The company announced positive results in the second population of its Phase II study of dazodalibep in patients with Sj

The Swedish biotech is expecting intense discussions with prospective partners for mitazalimab, a couple of years after Janssen returned the rights to the CD40 agonist.

Rather than making smaller investments in a larger number of areas, Orion is putting its research euros into oncology and pain management and pulling its Parkinson’s and Alzheimer’s projects, as well as its rare disease programs.

Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.